Citadel Advisors
ENFN

Citadel Advisors’s Enfusion, Inc. ENFN Stock Holding History

Citadel Advisors’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,300
Closed -$13.4K – 15899
2024
Q4 		$13.4K Buy
1,300
+700
+117% +$6.77K ﹤0.01% 13448
2024
Q3 		$5.69K Hold
600
– – ﹤0.01% 13467
2024
Q2 		$5.11K Buy
+600
New +$5.49K ﹤0.01% 13430
2024
Q1 		– Sell
-1,900
Closed -$18.4K – 15612
2023
Q4 		$18.4K Buy
1,900
+1,100
+138% +$10.3K ﹤0.01% 12688
2023
Q3 		$7.18K Sell
800
-15,600
-95% -$148K ﹤0.01% 13273
2023
Q2 		$184K Buy
+16,400
New +$145K ﹤0.01% 10018

Other funds holding ENFN

FMC
FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
LECM
Lead Edge Capital Management New York $408M AUM 4.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Citadel Advisors's ENFN Position: Q1 2025 in Review

Citadel Advisors sold out of Enfusion, Inc. (ENFN) in Q1 2025, closing a stake of 1,037,723 shares — an estimated $10.7M sold.

Citadel Advisors first reported a position in ENFN in Q4 2021 and held it in 11 quarters. The position peaked at $10.7M in Q4 2024. 132 funds tracked by Wall St. Rank hold ENFN as of Q1 2025.

  • Citadel Advisors reported no remaining Enfusion, Inc. position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,037,723 Enfusion, Inc. shares in Q1 2025, an estimated $10.7M.
  • Citadel Advisors first reported a position in Enfusion, Inc. in Q4 2021 and held it in 11 quarters.
  • Citadel Advisors's Enfusion, Inc. position peaked at $10.7M in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.